indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; and (3) BLA 125554/S-041, trade name OPDIVO (nivolumab), submitted by Bristol-Myers Squibb Company, indicated as a single agent for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
04-27-2021 01:00 PM - 04-29-2021 05:30 PM ET
Membership
JoinBenefitsRenew Your Membership
Privacy & Terms
About UsCode of Conduct